Our proposal was to generate patient IPSC organoids from several neurodevelopmental diseases and assess these ‘diseases in a dish’ for preclinical response to ASOs to correct disease-associated differential gene expression (DGE). We made excellent progress, and were able to grow patient neurons for all of the proposed conditions. We were able to identify DGE signatures for some but not all of the diseases. For one condition, we were able to demonstrate that ASOs can partially reverse the DGE signature. These results are promising, but more work is needed to robustly model neurodevelopmental disorders, and their response to treatment with ASOs.